- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
- Interventions
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Genetic · Radiation
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 10
- States / cities
- Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Ovarian Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- Genetic · Combination Product
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Augusta, Georgia + 6 more
- Conditions
- Synovial Sarcoma, Myxoid Liposarcoma
- Interventions
- afamitresgene autoleucel (previously ADP-A2M4)
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2038
- U.S. locations
- 17
- States / cities
- Duarte, California • Palo Alto, California • Aurora, Colorado + 13 more
- Conditions
- Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
- Interventions
- Afamitresgene autoleucel
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 7 more
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2037
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
- Conditions
- Neoplasms
- Interventions
- ADP adoptive cell therapy
- Biological
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 10 more
- Conditions
- Synovial Sarcoma, Myxoid Liposarcoma
- Interventions
- Non-conforming afamitresgene autoleucel
- Genetic
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more